z-logo
open-access-imgOpen Access
Management of AML Beyond “3 + 7” in 2019
Author(s) -
Jonathan Canaani
Publication year - 2019
Publication title -
clinical hematology international
Language(s) - English
Resource type - Journals
ISSN - 2590-0048
DOI - 10.2991/chi.d.190316.001
Subject(s) - medicine
The therapeutic paradigm for treatment of acute myeloid leukemia (AML) is rapidly changing with the advent of a new generation of drugs targeting diverse aspects of leukemogenesis. Whereas standard treatment for AML until recently consisted of a classic chemotherapy backbone, the incorporation of novel agents targeting pathogenic mutations, myeloid surface markers, and apoptosis-related proteins may become a reality in the next few years. In this review, we outline the therapeutic landscape of recently approved novel agents for AML, including FLT3 inhibitors, isocitrate dehydrogenase 1/2 ( IDH1/2 ) inhibitors, Bcl-2 antagonists, hedgehog signaling inhibitors, and immunotherapy-based approaches. Some of the future challenges in the field would be to delineate which specific patient subsets derive the most clinical benefit from a given novel agent and, furthermore, which drug combinations will yield the maximal antileukemia effect without increased toxicity. To this end, it is expected that advances in genomic and epigenomic classification of AML will facilitate a rational and optimal choice of these novel agents for AML patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here